复宏汉霖:就HLX13(重组抗CTLA-4全人单克隆抗体注射液)与Sandoz订立的许可协议

格隆汇
29 Apr

格隆汇4月29日丨复宏汉霖(02696.HK)公告,近日,公司与Sandoz AG("Sandoz")订立一份许可协议,据此,公司向Sandoz授出独家许可,供其于美国、约定的欧洲地区(42个欧洲国家)、日本、澳大利亚及加拿大("区域")内及领域(定义如下)内商业化HLX13(重组抗CTLA-4全人单克隆抗体注射液)("许可产品"或"HLX13")。HLX13是公司自主研发的伊匹木单抗生物类似药,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10